Dozens of congressional lawmakers are pressing the Department of Health and Human Services (HHS) to compel Eli Lilly to restore mandated drug price discounts for hospitals participating in the 340B federal drug discount program. This push follows the company’s recent decision to eliminate these discounts, citing concerns over duplicate discounts that hospitals may receive.
In a letter addressed to HHS Secretary Robert F. Kennedy Jr., the bipartisan group contends that Lilly’s actions contravene federal law, which requires compliance with the 340B program’s pricing structure. The company had previously halted discounts for approximately 50 larger hospital systems, targeting those that had not adhered to a newly established policy requiring claims data submission.
This situation raises significant implications for hospital funding and patient access to affordable medications, particularly as Lilly claims that around 70% of the participating hospitals have complied with the data requirements. The ongoing debate highlights the tension between pharmaceutical companies and healthcare providers in the context of federal drug pricing regulations.
Start your 7-day trial and see what the database can do →
